Onchocerciasis
28
3
6
15
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.1%
2 terminated out of 28 trials
88.2%
+1.7% vs benchmark
25%
7 trials in Phase 3/4
27%
4 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (28)
Host Response to Infection and Treatment in Filarial Diseases
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
Integrating Mental Health Into Neglected Tropical Disease Care in Ghana
Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
Safety and Efficacy of IDA for Onchocerciasis
Emodepside Phase II Trial for Treatment of Onchocerciasis
Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan
Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)